Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
Establishment Labs Holdings Inc (ESTA) provides innovative medical technologies for breast aesthetics and reconstruction. This news hub offers investors and healthcare professionals direct access to official updates, financial disclosures, and clinical advancements shaping this global medical device leader.
Key resources include: Earnings reports detailing financial performance, regulatory filings with global health authorities, and announcements of new product launches. Track developments in patented implant technologies and strategic partnerships across 40+ countries.
Bookmark this page for verified updates on surgical innovations, clinical trial results, and market expansion initiatives. Our curated news collection helps stakeholders monitor ESTA's progress in enhancing patient outcomes through advanced medical solutions.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced CEO Juan José Chacón-Quirós and CFO Renee Gaeta will participate in the BTIG Virtual MedTech Conference from February 17-19, 2021. They are scheduled to present at 10:00 am ET on February 19. The conference offers a platform for discussions on the company's focus on women's health, particularly in breast aesthetics with their Motiva Implants®.
A live webcast and archived presentation will be accessible on their investor relations website.
Establishment Labs Holdings (NASDAQ: ESTA), a medical technology firm specializing in women’s health, announced a virtual investor event on Feb. 9, 2021, to discuss its innovative Motiva Mia® system. This system aims to provide a minimally invasive breast enhancement procedure with reduced recovery time and less pain compared to traditional methods. Renowned medical professionals will share insights from a recent clinical study involving 30 patients. Despite this advancement, the Motiva Mia system is not yet commercially approved. Registration for the event is available online.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós will speak at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 4:30 PM ET. The conference will highlight the company's focus on women's health, particularly in breast aesthetics and reconstruction markets. A live webcast will be available for interested parties, with an archived version following the event. Establishment Labs is recognized for its Motiva Implants® and other innovative technologies, which are available in over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced preliminary revenue figures for Q4 and FY 2020. Q4 revenue is expected between $26.5 million and $27.5 million, marking a 10% to 13% increase from $24.2 million in Q4 2019 and up to 20% from Q3 2020. FY 2020 revenue is projected at $84.2 million to $85.2 million, above prior guidance of $80 to $82 million. Cash reserves as of December 31, 2020, are anticipated to be around $84 million, up from $81.4 million in Q3 2020. The CEO highlighted effective contingency planning and market share gains as key contributors to this growth.
Establishment Labs Holdings (NASDAQ: ESTA) announced the receipt of a CE mark for its Motiva Ergonomix2 silicone breast implant platform, which includes the Motiva Ergonomix2 Diamond implant. This approval paves the way for the launch of the Motiva Mia minimally invasive augmentation system in Europe. The Ergonomix2 features advanced materials and patented technology aimed at enhancing patient comfort and minimizing complications. The company anticipates commencing pre-commercial procedures in Europe in the latter half of 2021, significantly shortening the approval timeline by three years.
Establishment Labs (NASDAQ: ESTA) has received Institutional Review Board (IRB) approval for its Motiva Mia system, which features the Ergonomix2 Diamond breast implant. The approval allows the company to initiate a patient series in Costa Rica, with the first procedures already completed on 21 patients. This innovative system aims for minimally invasive breast augmentation with quicker recovery times and less pain. The company is also set to conduct a separate patient series in Thailand, expected to begin in Q1 2021.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focusing on women’s health in breast aesthetics and reconstruction, announced participation in two investment conferences. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will present at the Jefferies Virtual London Healthcare Conference from November 17-19, 2020, and at the Stephens Virtual Investment Conference from November 16-20, 2020. Presentations will be webcast live on their investor relations website, with archived versions available post-event.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported Q3 2020 revenue of $22.8 million, consistent with the prior year's figure. The company's full-year revenue forecast is set at $80 million to $82 million, supported by a 23% reduction in operating expenses to $17.7 million. This quarter's gross profit reached $15.1 million, representing a margin of 66.6%. The cash balance stood at $81.4 million with a reduced net loss of $2.6 million. New product developments and regulatory advancements bolster future growth potential.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported preliminary third-quarter 2020 revenue between $22 million and $23 million, consistent with $22.9 million from 2019 and significantly up from $10.5 million in Q2 2020. The company's cash balance was approximately $81.0 million as of September 30, 2020. CEO Juan José Chacón-Quirós expressed satisfaction with the quarter's performance, highlighting strong growth and effective cost management. Full third-quarter results will be announced on November 9, 2020.
